BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 16904455)

  • 1. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
    Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
    Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
    Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
    Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
    Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
    BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy.
    Okamura K; Takaba H; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Apr; 12(4):346-52. PubMed ID: 15948720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume.
    Stamey TA; Yemoto CE
    J Urol; 2000 Jan; 163(1):119-26. PubMed ID: 10604328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
    Tanaka N; Fujimoto K; Chihara Y; Torimoto M; Hirao Y; Konishi N; Saito I
    Prostate Cancer Prostatic Dis; 2007; 10(3):274-8. PubMed ID: 17339878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.
    Gjengstø P; Paus E; Halvorsen OJ; Eide J; Akslen LA; Wentzel-Larsen T; Hoisaeter PA
    J Urol; 2005 Feb; 173(2):425-8. PubMed ID: 15643193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
    Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
    Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population.
    Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
    Jpn J Clin Oncol; 2004 Oct; 34(10):602-7. PubMed ID: 15591458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
    Custovic Z; Kraus O; Tomaskovic I; Tarle M
    Anticancer Res; 2007; 27(4C):2817-21. PubMed ID: 17695453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
    Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
    J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.